

30th September 2021

The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001

The Secretary The National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C/1, G Block Bandra-Kurla Complex Bandra East, Mumbai - 400 050

Closing of transaction relating Slump Sale and transfer of the Nutraceuticals business of the Company

Dear Sirs,

This has reference to our letter dated 28th July 2021 wherein we intimated you that the Board of Directors of Sanofi India Limited (the Company) at its meeting held on 27th July 2021 approved a transaction for the slump sale and transfer of the Company's Nutraceuticals business, on a going concern basis to Universal Nutriscience Private Limited (Universal Nutriscience) for a consideration of Rs. 5,870 million including debt like obligations (such as retirals and provision for sales returns), subject to customary working capital adjustments and post-closing adjustment in connection with certain contractual arrangements between the parties. We had also intimated that the completion of this transaction is anticipated within three months, subject to fulfillment of conditions as set out in the Business Transfer Agreement.

We would like to inform you that after completion of conditions precedent as per Business Transfer Agreement, the transaction has been closed on 30th September 2021.

After the working capital adjustment on the closing date, the total consideration for the transaction has been calculated at Rs. 5,876.40 million. The Company has received the final consideration of Rs. 5,876.40 million on the closing date. This is subject to a customary postclosing working capital adjustment in accordance with the terms of the Business Transfer Agreement.

This is for your information and records.

For SANOFI INDIA LIMITED

VAIBHAV KARANDIKAR WHOLE TIME DIRECTOR, CFO & COMPLIANCE OFFICER